Purpose: To report the short-term results of a single intravitreal injection of bevacizumab (IVB) versus a single intravitreal injection of triamcinolone acetonide (IVT) to treat refractory noninfectious uveitic cystoid macular edema (CME). Methods: Twenty-eight consecutive patients (36 eyes) were retrospectively included. Patients received either 2.5mg of IVB (16 eyes) or 4mg of IVT (20 eyes). Results: In the IVT group, baseline best-corrected visual acuity (BCVA) was logMAR 1.1±0.2, and improved to 0.7±0.3 (p<.001) at 6 months. In the IVB group, baseline BCVA was logMAR of 1.2±0.4 and improved to 0.8±0.4 at 6 months (p.=031). At 6 months, central macular thickness (CMT) in the IVT group improved from 454.8±238.9μm to 296±134.4μm (p<.0001). Conclusion: A single IVT injection improves BCVA and reduces CMT more effectively than IVB in refractory noninfectious uveitic CME at 6 months.
- Noninfectious uveitis
- Single intravitreal injection
- Triamcinolone acetonide
- Uveitic cystoid macular edema
ASJC Scopus subject areas
- Immunology and Allergy